News
2d
MyChesCo on MSNMadrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH CirrhosisCONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced two-year results from the open-label arm of ...
Viking Therapeutics became famous in the biotech world last year after announcing positive phase 2 results for VK2735, an ...
On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...
We recently published an article titled Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals announced positive results from the Phase 3 MAESTRO-NAFLD-1 trial of their drug Rezdiffra, focusing on patients with compensated metabolic dysfunction-associated ...
GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...
Pritzker’s 8 Stocks with Huge Upside Potential. In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against Nicholas J. Pritzker’s other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results